Aprea Therapeutics (APRE) vs Soligenix (SNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Soligenix is the larger company by market cap ($8.0 million vs $7.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APRE | SNGX |
|---|---|---|
| Share price | $0.5831 | $0.3661 |
| Market cap | $7.34M | $7.97M |
| 1-day change | +4.46% | +5.63% |
| EPS (TTM) | $-0.95 | $-0.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.69 | $1.80 |
| 52-week low | $0.548 | $0.28 |
| Distance from 52-week high | -65.50% | -79.66% |
| Analyst consensus | none | none |
| Avg. price target upside | +539.68% | +276.95% |
| Average volume | 280.14K | 249.87K |
| Shares outstanding | 12.59M | 21.77M |
| Employees | 8 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aprea Therapeutics
APRE stock →Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About Soligenix
SNGX stock →Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
APRE vs SNGX FAQ
Which is bigger, Aprea Therapeutics or Soligenix?
Soligenix (SNGX) is larger, with a market capitalization of $7.97M compared with $7.34M for Aprea Therapeutics (APRE).
Are Aprea Therapeutics and Soligenix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.